Preclinical Development Of A Humanised Antibody To C5aR.
Funder
National Health and Medical Research Council
Funding Amount
$124,875.00
Summary
Complement factor C5a is one of the most potent inflammatory mediators in the body. We have developed a monoclonal antibody that blocks the C5a receptor in vitro, and completely shuts down disease in a mouse model of rheumatoid arthritis. We plan to develop this promising new antibody into a potent therapy to treat a range of chronic and acute inflammatory diseases. The antibody has been humanised and this will be tested in three models of inflammation (rheumatoid arthritis, sepsis and colitis) ....Complement factor C5a is one of the most potent inflammatory mediators in the body. We have developed a monoclonal antibody that blocks the C5a receptor in vitro, and completely shuts down disease in a mouse model of rheumatoid arthritis. We plan to develop this promising new antibody into a potent therapy to treat a range of chronic and acute inflammatory diseases. The antibody has been humanised and this will be tested in three models of inflammation (rheumatoid arthritis, sepsis and colitis) to determine the efficacy of the antibody, safety, the most effective dose, timing and route of administration. These studies are a necessary prelude to human clinical trials, which we hope to perform in approximately 24 months.Read moreRead less
Human cytomegalovirus (HCMV) is a classic example of a group of herpes viruses, which is found universally throughout all geographic locations and socioeconomic groups, and infects 50% of adults in developed countries. HCMV infection is important to certain high-risk groups. Major areas of concern are: (1) the risk of infection to unborn baby during pregnancy, (2) the risk of infection to people who work with children, and (3) the risk of infection to immunocompromised persons (e.g. organ transp ....Human cytomegalovirus (HCMV) is a classic example of a group of herpes viruses, which is found universally throughout all geographic locations and socioeconomic groups, and infects 50% of adults in developed countries. HCMV infection is important to certain high-risk groups. Major areas of concern are: (1) the risk of infection to unborn baby during pregnancy, (2) the risk of infection to people who work with children, and (3) the risk of infection to immunocompromised persons (e.g. organ transplant patients and HIV-infected individuals). Epidemiological studies have shown that 80%-90% of developing unborn babies who acquire congenital HCMV infection displays a variable pattern of pathological sequelae within the first few years of life that may include hearing loss, vision impairment and mental retardation. There is an increasing argument that a reduction in HCMV load will have a significant effect on the sequelae associated with congenital HCMV infection. Indeed, vaccination provides the most practical modality of achieving such a reduction in HCMV load. To develop such a vaccine, formulation based on viral antigens that activate both protective cellular and humoral responses needs to be tested to assess its immunogenicity. No such vaccine is presently available for HCMV. In this application we have sought to develop a prophylactic vaccine and to test its efficacy in a immunocompetent transgenic mouse model and as well under conditions of immunosuppression (CD4 T cell deficient). The overall strategy is to use this prophylactic vaccine to stimulate the cellular (CD8+ and CD4+ T cells) and humoral responses against multiple HCMV antigens. This vaccine will be based on the novel chimeric polyepitope technology and exploits a novel replication deficient adenovirus expression system which has recently been approved for human use.Read moreRead less
Exploiting the lymphatic system for next generation vaccine development . Vaccination is the most successful and cost-effective means of combating infectious diseases. This project will look at how vaccine adjuvants work and will help the development of new vaccines against infections in both animals and man. It will also promote the training of Australian scientists in the field of vaccine research and development.
HIV currently infects ~40 million people world-wide, causing ~3 million deaths in 2003, mainly in the world's poorest countries. A cheap, effective vaccine seems the best means of preventing the spread of the epidemic. The two main approaches to vaccination are either to make antibodies (which bind to and inactivate the virus), or killer T cells (which kill infected cells). Many of these vaccines are now being tested in monkeys. The results of killer T cell vaccination trials have been both enco ....HIV currently infects ~40 million people world-wide, causing ~3 million deaths in 2003, mainly in the world's poorest countries. A cheap, effective vaccine seems the best means of preventing the spread of the epidemic. The two main approaches to vaccination are either to make antibodies (which bind to and inactivate the virus), or killer T cells (which kill infected cells). Many of these vaccines are now being tested in monkeys. The results of killer T cell vaccination trials have been both encouraging and disappointing. The vaccines do not appear able to prevent the monkeys from getting infected with the virus. However, in many cases even though the monkeys become infected with HIV, they do not get the usual disease associated with AIDS, and hence live with rather than die from this infection. The aims of this project are to use statistical analysis, and more complex mathematical and computer models to try to analyse the data generated by these vaccine trials and to understand how these partially effective vaccines help control virus. For example, even if a vaccine does not prevent infection, we can investigate whether it slowed viral growth, or increased killing of infected cells, and if so, whether an increase in this response could be effective. In preliminary work we have analysed data from a vaccination trial performed in Boston. The results of this study suggest that the reason vaccinated monkeys still become infected is that the killer T cells produced by the vaccine do not appear to activate for the first 10 days of infection. In these first 10 days the virus grows normally and is able to establish a foothold for continuing infection. By contrast, we find that antibodies act extremely early after infection. The methods we propose have not been used before to study vaccines, and by studying the kinetics of the virus and immune response from a large number of vaccine trials we hope to help identify the optimal vaccine design.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE240100827
Funder
Australian Research Council
Funding Amount
$458,737.00
Summary
Delineating the developmental requirements for stem-like T cells. Stem-like CD8 T cells are critical for sustaining long-term systemic T cell activity. The signalling required for their development, however, remains elusive. Integrating multidisciplinary expertise, cutting-edge technology and highly innovative methods, this project aims to define the signalling cues provided by tissue microenvironment that control the development and maintenance of stem-like T cells, and thereby dictate systemic ....Delineating the developmental requirements for stem-like T cells. Stem-like CD8 T cells are critical for sustaining long-term systemic T cell activity. The signalling required for their development, however, remains elusive. Integrating multidisciplinary expertise, cutting-edge technology and highly innovative methods, this project aims to define the signalling cues provided by tissue microenvironment that control the development and maintenance of stem-like T cells, and thereby dictate systemic immunity. This project is expected to generate fundamental knowledge on basic immunology and T cell biology, which can benefit the academic, public health and biotechnology sectors by enhancing the international standing of Australian research on basic immunology and fostering new commercial opportunities. Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE210100705
Funder
Australian Research Council
Funding Amount
$462,948.00
Summary
Decoding the enigmatic biology of human gamma-delta T cells. The immune system surveys our body examining molecules that signal whether or not everything is ok. T cells are a central to this and use their receptors to monitor these molecular signals. A specialised subset of T cells known as gamma-delta T cells are critical to detecting infection and cancer, yet their fundamental biology is poorly understood. This project aims to unravel this elusive biology. The aims are to understand 1. The div ....Decoding the enigmatic biology of human gamma-delta T cells. The immune system surveys our body examining molecules that signal whether or not everything is ok. T cells are a central to this and use their receptors to monitor these molecular signals. A specialised subset of T cells known as gamma-delta T cells are critical to detecting infection and cancer, yet their fundamental biology is poorly understood. This project aims to unravel this elusive biology. The aims are to understand 1. The diversity in function between gamma-delta T cell subsets, and 2. The diversity in gamma-delta T cell receptors and the molecules that these receptors detect. This work is essential for understanding gamma-delta T cell immunology which is critical if we ultimately wish to harness this to improve human health.Read moreRead less
Enhanced multivalent vaccine responses using a novel vaccine vector system. Enhanced multivalent vaccine responses using a novel vaccine vector system. This project aims to develop a multicomponent vaccine system to deliver equal effectiveness against several disease targets in a single administration. New and innovative vaccine design strategies incorporating economical commercial production processes are urgently needed for new and existing human and animal health applications. A vaccine capab ....Enhanced multivalent vaccine responses using a novel vaccine vector system. Enhanced multivalent vaccine responses using a novel vaccine vector system. This project aims to develop a multicomponent vaccine system to deliver equal effectiveness against several disease targets in a single administration. New and innovative vaccine design strategies incorporating economical commercial production processes are urgently needed for new and existing human and animal health applications. A vaccine capable of targeting multiple diseases by a single injection is an obvious way to expedite future vaccine development and deployment. However, the recipient’s immune system can repress equivalent responses to these multicomponent vaccines. This project’s research is expected to address these problems, and underpin the future commercial development of this vaccine platform.Read moreRead less
Real-time analysis of tumour-infiltrating T cells using novel analytical tools. By dynamic visualization of immune cells within intact tumours, we have shown that active screening for target cells optimises their anti-tumour effect. This project will develop novel mathematical/analytical tools to unravel the basic strategies that enable immune cells to position themselves at the right location at the right time.
Epigenetic regulation of immune memory. Immune memory cells emerge from the dynamic and transient immune response to deliver two critical abilities: to produce rapid recall responses upon reinfection but also to persist for decades. This project aims to define how the polycomb repressive complexes regulate immune cell fate, by utilising cutting-edge cell and chromatin biology techniques coupled with bioinformatic pipelines. Expected outcomes of the proposed research include key insights into epi ....Epigenetic regulation of immune memory. Immune memory cells emerge from the dynamic and transient immune response to deliver two critical abilities: to produce rapid recall responses upon reinfection but also to persist for decades. This project aims to define how the polycomb repressive complexes regulate immune cell fate, by utilising cutting-edge cell and chromatin biology techniques coupled with bioinformatic pipelines. Expected outcomes of the proposed research include key insights into epigenetic programming required for immune cell differentiation and longevity. This should provide significant benefits such as knowledge creation that may lead to development of technology that reprograms cell behaviour, and contribution to Australian research recognition and capacity.Read moreRead less